NCT00586495 - Long-term Extension From RCC Phase II (11515) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally

Trial Locations (41)

010-8543

Akita

289-2511

Asahi

260-8677

Chiba

260-8717

Chiba

791-0280

Matsuyama

812-0033

Fukuoka

812-8582

Fukuoka

830-0011

Kurume

372-0817

Isesaki

371-8511

Maebashi

003-0804

Sapporo

060-8543

Sapporo

060-8648

Sapporo

073-0196

Sunagawa

305-8576

Tsukuba

020-8505

Morioka

890-8520

Kagoshima

602-8566

Kyoto

606-8507

Kyoto

514-8507

Tsu

981-1293

Natori-shi

634-8522

Kashihara

710-8602

Kurashiki

700-8558

Okayama

537-8511

Osaka

589-8511

Sayama

565-0871

Suita

350-1298

Hidaka

350-0495

Irima-gun

359-8513

Tokorozawa

431-3192

Hamamatsu

411-8777

Sunto

320-0834

Utsunomiya

770-8503

Tokushima

116-8567

Arakawa-ku

113-8655

Bunkyo-ku

104-0045

Chuo-ku

173-0003

Itabashi-ku

162-8666

Shinjuku-ku

990-9585

Yamagata

755-8505

Ube